CAR-T cell therapy has shown promising results in the treatment of leukemia and non-Hodgkin's lymphoma (NHL) in Europe. In these diseases, CAR-T cell therapy targets specific proteins, known as antigens, that are expressed on the surface of leukemia or lymphoma cells. The specific antigen targeted by the CAR-T cells can vary depending on the type of leukemia or lymphoma being treated.
For example, in the case of acute lymphoblastic leukemia (ALL), CAR-T cell therapy has been developed to target the CD19 antigen, which is expressed on the surface of B-cell leukemia cells. CD19-targeted CAR-T cell therapy has been shown to induce complete remission in a significant proportion of patients with relapsed or refractory ALL.
In the case of NHL, the CD19 antigen is also a common target for CAR-T cell therapy, but other antigens, such as CD20, CD22, and BCMA, may also be targeted depending on the subtype of NHL being treated. For example, in the case of diffuse large B-cell lymphoma (DLBCL), which is the most common subtype of NHL, CAR-T cell therapy targeting CD19 has been shown to induce high rates of durable response in patients who have relapsed or refractory disease.
It's worth noting that CAR-T cell therapy is a complex and highly specialized treatment that is typically administered at specialized treatment centers by experienced healthcare professionals.
Below are the names of some specialized treatment centers in Europe that offer CAR-T cell therapy for leukemia and lymphoma:
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK - for pediatric patients
- University College London Hospitals NHS Foundation Trust, London, UK
- King's College Hospital NHS Foundation Trust, London, UK
- The Christie NHS Foundation Trust, Manchester, UK
- Hospital Clinic Barcelona, Barcelona, Spain
- University Hospital Würzburg, Würzburg, Germany
- University Hospital Heidelberg, Heidelberg, Germany
- Gustave Roussy Cancer Campus, Villejuif, France
- Assistance Publique-Hôpitaux de Paris, Paris, France
- University Hospitals Leuven, Leuven, Belgium
This is not an exhaustive list, and there may be other specialized treatment centers in Europe that offer CAR-T cell therapy for leukemia and lymphoma. It's important to consult with a healthcare provider to determine if CAR-T cell therapy is an appropriate treatment option based on an individual's specific condition and circumstances.
CAR-T therapy cost in Europe
The cost of CAR-T therapy in Europe can vary depending on the specific therapy being used, the country in which it is being administered, and the patient's insurance coverage. However, CAR-T therapy is generally expensive due to its complex manufacturing process and personalized nature.
In Europe, the cost of CAR-T therapy for the treatment of blood cancer can range from tens of thousands to hundreds of thousands of euros. For example, the cost of tisagenlecleucel, a CAR-T therapy approved in Europe for the treatment of certain types of blood cancer, has been reported to be around €320,000 (approximately 380,000 US dollars) per treatment.
However, many European countries have national healthcare systems that cover a portion of the cost of medical treatments, including CAR-T therapy.
CAR-T cell therapy in Israel
CAR-T for Leukemia and Lymphoma in Israel
CAR-T for Myeloma in Israel
CAR-T cell therapy for Multiple Myeloma patients in Europe
CAR-T Cell Therapy for Blood Cancers: A Global Overview